Solana Analyst Price Targets - Benzinga

Solana Co

HSDTNASDAQ

Trade with Public

Trade with Public

$2.63

0.010.38%

Dern. MÀJ: Oct 2, 7:31 PM

$2.67

0.051.91%

Aperçu Actualités Prévisions de résultats ÉvénementsObjectifs de coursDonnées financières Sentiment Actionnariat Comparer Options Rapport sur les stocks

Solana Analyst Price Targets - Benzinga

Solana Analyst Price Targets

Wall Street analyst price targets and consensus rating for Solana (HSDT).

Price Target Range — 3 Quarters

Analyst Consensus — 3 Analysts

3Buy

Consensus RatingBuy# Analysts3Avg. Consensus PT$6003Upside to Avg. PT+224719.1%

Rating Trend — Last 9 Months

Recent Analyst Actions

Voir toutes les évaluations →

Date	Firm	Analyst	Action	Rating Change	Price Target
Sep 22, 2026	B. Riley Securities	Fedor Shabalin	PT Raise	Buy	$4→$4
Sep 3, 2026	B. Riley Securities	Fedor Shabalin	PT Raise	Buy	$3→$4
Aug 17, 2026	B. Riley Securities	Fedor Shabalin	PT Cut	Buy	$3→$3
Apr 6, 2026	Maxim Group	Matthew Galinko	Assumes	Hold→Buy	$4
Oct 16, 2024	Maxim Group	Anthony Vendetti	Downgrade	Buy→Hold	—
Mar 5, 2024	Roth MKM	Jonathan Aschoff	Maintained	Buy	$5→$24

More with Benzinga EdgeGet Access

Analyst Ratings News

PRO
B. Riley Securities Maintains Buy on Solana, Raises Price Target to $4

B. Riley Securities analyst Fedor Shabalin maintains Solana (NASDAQ:HSDT) with a Buy and raises the price target from $3.5 to $4.

Benzinga Newsdesk

PRO
B. Riley Securities Maintains Buy on Solana, Raises Price Target to $3.5

B. Riley Securities analyst Fedor Shabalin maintains Solana (NASDAQ:HSDT) with a Buy and raises the price target from $2.5 to $3.5.

Benzinga Newsdesk

PRO
B. Riley Securities Maintains Buy on Solana, Lowers Price Target to $2.5

B. Riley Securities analyst Fedor Shabalin maintains Solana (NASDAQ:HSDT) with a Buy and lowers the price target from $3 to $2.5.

Benzinga Newsdesk

PRO
Maxim Group Downgrades Helius Medical Tech to Hold

Maxim Group analyst Anthony Vendetti downgrades Helius Medical Tech (NASDAQ:HSDT) from Buy to Hold.

Benzinga Newsdesk

PRO
Roth MKM Maintains Buy on Helius Medical Tech, Adjusts Price Target To $24

Roth MKM analyst Jonathan Aschoff maintains Helius Medical Tech (NASDAQ:HSDT) with a Buy, adjusts target to $24 from $5.

Benzinga Newsdesk

PRO
Hearing Roth Capital Partners Raises Helius Medical Technologies PT To $24

Benzinga Newsdesk